MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025

Financial Results Announcement - MannKind Corporation will release its first quarter 2025 financial results before market open on May 8, 2025 [1] - A webcast will be hosted at 9:00 a.m. Eastern Time to discuss the financial results and provide a business update [2] Company Overview - MannKind Corporation focuses on the development and commercialization of innovative inhaled therapeutic products and devices for serious unmet medical needs related to endocrine and orphan lung diseases [3] - The company aims to address diseases such as diabetes, nontuberculous mycobacterial lung disease, pulmonary fibrosis, and pulmonary hypertension through its formulation capabilities and device engineering [4] Technology and Mission - MannKind's signature technologies include dry-powder formulations and inhalation devices that enable rapid and convenient delivery of medicines to the deep lung [4] - The company is committed to empowering individuals to take control of their health and improve their quality of life [5]